Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …

Cancer immunotherapy critically depends on fitness of cytotoxic and helper T cell
responses. Dysfunctional cytotoxic T cell states in the tumor microenvironment (TME) are a …

Gliomas are the most prevalent and devastating primary malignant brain tumors in adults.
Despite substantial advances in understanding glioma biology, there have been no …

Immuno-oncology, specifically immune checkpoint inhibitors (ICIs), has revolutionized
cancer care with dramatic, long-term responses and increased survival, including patients …

Stimulating the innate immune system has been explored as a therapeutic option for the
treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH …

Tumors growing in metabolically challenged environments, such as glioblastoma in the
brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy …

Glioblastoma (GBM) is an aggressive primary brain tumor with a dismal prognosis. Given the
paucity of tumor infiltrating lymphocytes (TILs), an immune suppressive tumor …

Advances in single-cell RNA-sequencing (scRNA-seq) technology enable unbiased, whole
transcriptome profiling of tissues, which have revolutionized systems-level studies of these …

Glioblastoma (GBM) is the most aggressive type of glioma (Grade IV). The presence of
cytotoxic T lymphocyte (CTLs) has been associated with improved outcomes in patients with …